This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Nuvalent’s 8K filing here.
Nuvalent Company Profile
Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.
See Also
- Five stocks we like better than Nuvalent
- How to Capture the Benefits of Dividend Increases
- How to Master Trading Discipline: Overcome Emotional Challenges
- What is the NASDAQ Stock Exchange?
- Does China Investigation Change NVIDIA’s Outlook; Yes, No, Maybe?
- What to Know About Investing in Penny Stocks
- Is Marvell Technology Chipping Away at NVIDIA’s Market Lead?